JUVENTAS
Juventas is a provider and developer of innovative immune cell therapeutic drugs. The company's first investigational new drug application for the cell therapeutic product CNCT19 has been officially accepted by the National Medical Products Administration. Comprehensive product pipelines will be developed and promoted constantly to provide effective treatment for malignant hematological neoplasms such as leukemia and lymphoma.
JUVENTAS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2018-01-01
Address:
Chaoyang, Liaoning, China
Country:
China
Website Url:
http://www.juventas.cn
Total Employee:
11+
Status:
Active
Contact:
010-65960098
Email Addresses:
[email protected]
Total Funding:
101.57 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Mobile Non Scaleable Content Nginx Microsoft Azure DNS PHP PHP 7 Apple Mobile Web App Capable Apple Mobile Web App Status Bar Style
Current Employees Featured
Founder
Investors List
Ding Xiang Capital
Ding Xiang Capital investment in Series C - Juventas
Dalton Venture
Dalton Venture investment in Series C - Juventas
Delian Capital
Delian Capital investment in Series C - Juventas
CICC
CICC investment in Series C - Juventas
Redhill Capital
Redhill Capital investment in Series C - Juventas
Jiadao Capital
Jiadao Capital investment in Series C - Juventas
Haisong Capital
Haisong Capital investment in Series C - Juventas
Tianchuang Zhixing (Beijing) Touzi Guanli Zixun Youxian Gongsi
Tianchuang Zhixing (Beijing) Touzi Guanli Zixun Youxian Gongsi investment in Series C - Juventas
Tianjin Venture Capital
Tianjin Venture Capital investment in Venture Round - Juventas
CASI Pharmaceuticals
CASI Pharmaceuticals investment in Series A - Juventas
More informations about "Juventas"
合源生物科技（天津）有限公司 - 首页
合源生物首个核心产品 - 源瑞达®（纳基奥仑赛注射液，CNCT19，Inaticabtagene Autoleucel Injection）是具有自主知识产权的靶向CD19的CAR-T细胞治疗产品，拥有全球独特的CD19 …See details»
Juventas - Crunchbase Company Profile & Funding
Juventas is a provider and developer of innovative immune cell therapeutic drugs. The company's first investigational new drug application for the cell therapeutic product CNCT19 has been officially accepted by the National Medical …See details»
Juventas Cell Therapy Ltd. (合源生物科技（天津）有限公司) - 药物 …
了解Juventas Cell Therapy Ltd. (合源生物科技（天津）有限公司)公司的药物管线，治疗领域，技术平台，以及它的29项临床试验, 336篇新闻和14篇文献，疾病领域:肿瘤，血液及淋巴系统疾 …See details»
WuXi Advanced Therapies Supports First …
SHANGHAI, November 8, 2023 – WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO) congratulates its customer, Juventas Cell Therapy, on achieving China’s …See details»
Juventas Company Profile - Office Locations, Competitors ... - Craft
Juventas Cell Therapy (合源生物) is a biopharmaceutical company focused on research and development of immune cell therapy products. It provides treatments for acute lymphoblastic …See details»
Juventas Cell Therapy Announces the Approval of Its First Cell …
Nov 10, 2023 Juventas Cell Therapy Ltd. announces China National Medical Product Administration (NMPA) has approved its New Drug Application (NDA) for Inaticabtagene …See details»
Juventas Cell Therapy Announces the Approval of Its …
Nov 10, 2023 About Juventas. Established in June 2018, Juventas Cell Therapy Ltd, a biopharmaceutical company powered by cutting-edge cell and gene technologies, has become the leader of innovative CGT drug development in …See details»
Juventas - Overview, News & Similar companies | ZoomInfo.com
Dec 3, 2019 Juventas contact info: Phone number: +86 1065960098 Website: www.juventas.cn What does Juventas do? Juventas Cell Therapy Ltd. is a China-based domestic …See details»
Juventas Cell Therapy Announces the Approval of Its First Cell …
Nov 10, 2023 BEIJING, TIANJIN, SHANGHAI, China., - NOVEMBER 10, 2023- Juventas Cell Therapy Ltd. announces China National Medical Product Administration (NMPA) has approved …See details»
Shanghai Juvensis Therapeutics Biotechnology - VentureRadar
Juventas Cell Therapy Ltd. is a biopharmaceutical company focusing on the R&D and commercialization of innovative drugs such as immune cell therapy, which has in-depth …See details»
全球首例！合源生物纳基奥仑赛治疗难治性系统性红斑狼疮相关免 …
北京时间2024年7月25日，国际顶级期刊《新英格兰医学杂志》 (《New England Journal Of Medicine》，NEJM，IF：96.2)在线发表了北京协和医院风湿免疫科曾小峰教授、李梦涛教授 …See details»
Juventas - Funding, Financials, Valuation & Investors - Crunchbase
Juventas is a provider and developer of innovative immune cell therapeutic drugs. ... How much funding has this organization raised over time? Show . Announced Date . Transaction Name ...See details»
Juventas Cell Therapy Ltd. Closes Series C Financing to Advance …
Jul 20, 2021 Juventas builds profound cooperation with China's leading hospitals and clinical research institutes and is committed to constructing a preeminent platform for cell therapy …See details»
Juventas Cell Therapy closes a $63M funding round as it eyes a big …
Oct 25, 2021 Juventas has grabbed a $63 million series C to advance its CASI Pharmaceuticals-partnered drug CNCT19. The new swag will be used toward an NDA for the cell therapy as it …See details»
Chinese cell therapy firm Juventas snaps up $63m Series C
Oct 26, 2021 Juventas, a Chinese cell therapy firm, has raised about $63 million in Series C funding. Iris Dorbian - 26 October 2021. Share A-A + 100%. Juventas, a Chinese cell therapy …See details»
Investee Company: Juventas has raked in over 400 million yuan in …
Jul 12, 2021 Founded in June 2018, Juventas Cell Therapy Ltd. is a biomedical enterprise focusing on the R&D and commercialization of innovative drugs such as immune cell therapy, …See details»
Juventas Cell Therapy Ltd. Closes Series C Financing to Advance …
TIANJIN, China, July 20, 2021 /PRNewswire/ -- Juventas Cell Therapy Ltd., a Chinese biopharmaceutical company announced the close of a $60 million+ Series C financing led by …See details»
媒体聚焦 | 《中国高新技术产业导报》整版报道高新区聚力打造“四 …
3 月 6 日 《中国高新技术产业导报》 整版报道了高新区. 在天津“十项行动”中. 谋好“高新篇章” 展现“高新作为” 2022 年，天津滨海高新区地区生产总值增长 7.7% ，规模以上工业总产值增长 …See details»
Juventas Lands ￥400 Million Series C Funding - vbdata.cn
(VCBeat) July. 12, 2021 -- Juventas Cell Therapy Ltd. ("Juventas") today announced the closing of a Series C financing of over 400 million RMB. This round of financing was jointly led by …See details»